U.S. markets closed

Aspira Women's Health Inc. (AWH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5144-0.0016 (-0.31%)
At close: 04:00PM EDT
0.5401 +0.03 (+5.00%)
After hours: 05:17PM EDT

Aspira Women's Health Inc.

Building III
Suite 100 12117 Bee Caves Road
Austin, TX 78738
United States
512 519 0400

IndustryDiagnostics & Research
Full Time Employees106

Key Executives

NameTitlePayExercisedYear Born
Ms. Valerie Barber PalmieriExec. Chairman574.91kN/A1961
Ms. Nicole Sandford CPAPres, CEO & Director22kN/A1970
Mr. Robert Harry Beechey CPAChief Financial Officer378.68kN/A1963
Mr. Sean RoweHead of TechnologyN/AN/AN/A
Ms. Minh MerchantGen. Counsel & Corp. Sec.N/AN/AN/A
Ms. Emily GrangerDirector of MarketingN/AN/AN/A
Mr. Gregory RichardHead of Corp. Strategy, Reimbursement & Managed CareN/AN/A1967
Dr. Charles J. Dunton M.D.Interim Chief Medical OfficerN/AN/AN/A
Mr. Michael J. NewtonHead of CommercialN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Corporate Governance

Aspira Women's Health Inc.’s ISS Governance QualityScore as of June 1, 2022 is 6. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.